# SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery

> **NCT03722875** · NA · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** SHR-1210
- **DRUG:** apatinib

## Key facts

- **NCT ID:** NCT03722875
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-01
- **Primary completion:** 2019-03-01
- **Final completion:** 2020-03-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03722875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03722875, "SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03722875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*